文献速递眼底病与葡萄膜炎

镰状细胞视网膜病变成人视网膜变薄纵向评估

Longitudinal Assessment of Retinal Thinning in Adults With and Without Sickle Cell Retinopathy Using Spectral-Domain Optical Coherence Tomography.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

这项纵向前瞻性病例对照研究纳入370名成人(711眼),使用频谱域OCT每年随访,比较伴与不伴镰状细胞视网膜病变者的视网膜变薄速率。结果显示,镰状细胞组在内鼻、内上、内颞和外鼻象限的变薄速率显著高于对照组,且SC和β-地中海贫血亚型变薄更快;羟基脲治疗与变薄速率降低相关。

要点

  • 镰状细胞视网膜病变患者内鼻、内上、内颞和外鼻象限视网膜变薄速率显著高于对照组。
  • SC和β-地中海贫血亚型患者视网膜变薄速率高于SS亚型。
  • 年龄、视网膜病变分期、卒中史、高血压、急性胸部综合征或糖尿病与更快的视网膜变薄相关。

核心结论

  • 伴镰状细胞视网膜病变的成人视网膜变薄速率高于不伴该病变者,且变薄速率随年龄和视网膜病变分期增加。

研究设计与样本

  • 纵向前瞻性病例对照研究,2009年2月11日至2019年7月3日从大学附属视网膜专科门诊招募成人参与者,按年龄和种族匹配。
  • 共纳入370名成人(711眼),其中镰状细胞视网膜病变组310人(606眼),对照组60人(105眼)。
  • 分析纳入至少随访1年的参与者:镰状细胞组175/310人(56.5%;344/606眼,56.8%),对照组31/60人(51.7%;46/105眼,43.8%)。
  • 镰状细胞组平均(SD)随访53.7(32.6)个月,对照组54.6(34.9)个月。

主要发现

  • 镰状细胞组较对照组视网膜变薄速率差异:内鼻象限-1.18 μm/年(95%CI,-1.71至-0.65),内上象限-1.03 μm/年(95%CI,-1.78至-0.29),内颞象限-0.61 μm/年(95%CI,-1.16至-0.07),外鼻象限-0.41 μm/年(95%CI,-0.80至-0.03)。
  • 镰状细胞血红蛋白SC和β-地中海贫血亚型患者视网膜变薄速率高于血红蛋白SS亚型患者。
  • 与更快视网膜变薄相关的危险因素包括参与者年龄、视网膜病变分期、既往卒中、高血压、急性胸部综合征或糖尿病。
  • 羟基脲治疗与视网膜变薄速率降低相关,可能为保护因素。

关键数值与推荐

  • 主要结局为比较伴与不伴镰状细胞视网膜病变眼之间以及不同镰状细胞血红蛋白亚型之间早期治疗糖尿病视网膜病变研究子区域的视网膜变薄速率。
  • 次要结局为识别与视网膜变薄速率相关的眼部及全身危险因素。

临床怎么用

  • 频谱域OCT识别镰状细胞黄斑病变的解剖学恶化可能有助于评估镰状细胞视网膜病变的进展。
  • 对镰状细胞病患者可考虑年度频谱域OCT随访,尤其关注内鼻、内上、内颞和外鼻象限的视网膜厚度变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Determination of retinal thinning rates may help to identify patients who are at risk of progression of sickle cell retinopathy. OBJECTIVE: To assess the rates of macular thinning in adults with and without sickle cell retinopathy using spectral-domain optical coherence tomography (OCT) and to identify ocular and systemic risk factors associated with retinal thinning. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal prospective case-control study enrolled adult participants from a university-based retina subspecialty clinic between February 11, 2009, and July 3, 2019. The study was designed in autumn 2008 and conducted from February 2, 2009, to July 3, 2020. Participants with sickle cell retinopathy (sickle cell group) were matched by age and race with participants without sickle cell retinopathy (control group). Participants received annual spectral-domain OCT and clinical examinations. Those with at least 1 year of follow-up by July 3, 2020, were included in the analysis. Data were analyzed from February 2, 2009, to July 3, 2020. MAIN OUTCOMES AND MEASURES: The primary outcome was comparison of spectral-domain OCT measurements from early-treatment diabetic retinopathy study subfield rates of retinal thinning between eyes with and without sickle cell retinopathy and between different sickle cell hemoglobin subtypes. The secondary outcome was identification of ocular and systemic risk factors associated with rates of retinal thinning. RESULTS: Among 370 adults (711 eyes) enrolled in the study, 310 participants (606 eyes) had sickle cell retinopathy, and 60 participants (105 eyes) did not. Of those, 175 of 310 participants (56.5%; 344 of 606 eyes [56.8%]; mean [SD] age, 37.8 [12.8] years; 126 women [72.0%]) in the sickle cell group and 31 of 60 participants (51.7%; 46 of 105 eyes [43.8%]; mean [SD] age, 59 [15.4] years; 22 women [71.0%]) in the control group had at least 1 year of clinical and spectral-domain OCT follow-up data from baseline. The mean (SD) follow-up was 53.7 (32.6) months for the sickle cell group and 54.6 (34.9) months for the control group. Rates of macular thinning in the sickle cell group were significantly higher than those in the control group for the inner nasal (difference, -1.18 μm per year; 95% CI, -1.71 to -0.65 μm per year), inner superior (difference, -1.03 μm per year; 95% CI, -1.78 to -0.29 μm per year), inner temporal (difference, -0.61 μm per year; 95% CI, -1.16 to -0.07 μm per year), and outer nasal (difference, -0.41 μm per year; 95% CI, -0.80 to -0.03 μm per year) quadrants. Patients with sickle cell hemoglobin SC and sickle cell hemoglobin β-thalassemia subtypes had higher rates of retinal thinning than those with the sickle cell hemoglobin SS subtype. Risk factors associated with greater rates of retinal thinning included participant age, stage of retinopathy, previous stroke, and presence of hypertension, acute chest syndrome, or diabetes. Hydroxyurea therapy was associated with decreased rates of retinal thinning and may be a protective factor. CONCLUSIONS AND RELEVANCE: In this study, rates of retinal thinning were higher among participants with sickle cell retinopathy compared with those without sickle cell retinopathy, and thinning rates increased with participant age and stage of retinopathy. These findings suggest that identifying anatomic worsening of sickle cell maculopathy through spectral-domain OCT may be a useful parameter to evaluate the progression of sickle cell retinopathy.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Lim JI, Niec M, Sun J, et al. Longitudinal Assessment of Retinal Thinning in Adults With and Without Sickle Cell Retinopathy Using Spectral-Domain Optical Coherence Tomography. JAMA Ophthalmol. 2021. PMID: 33538815. doi:10.1001/jamaophthalmol.2020.6525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。